US Stock MarketDetailed Quotes

CNTB Connect Biopharma

Watchlist
  • 1.0300
  • +0.0595+6.13%
Close Nov 27 16:00 ET
56.76MMarket Cap-2641P/E (TTM)

About Connect Biopharma Company

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Company Profile

SymbolCNTB
Company NameConnect Biopharma
Listing DateMar 19, 2021
Issue Price17.00
Founded2015
CEODr. Zheng Wei, PhD
MarketNASDAQ
Employees81
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressScience & Technology Park,3/F, East R&D Building,6 Beijing West Road
CityTaicang
ProvinceJiangsu
CountryChina
Zip Code215400
Phone86-512-53577866
Websitehttp://www.connectbiopharm.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Zheng Wei, PhD
  • Chief Executive Officer and Director
  • --
  • Steven Chan
  • Chief Financial Officer
  • --
  • Dr. Wubin Pan, PhD
  • Chairman of the Board and President
  • --
  • Dr. Kan Chen, PhD
  • Independent Director
  • --
  • Jean I. Liu
  • Independent Director
  • --
  • Karen J. Wilson
  • Independent Director
  • --
  • James Z. Huang
  • Independent Director
  • --
  • Dr. Kleanthis G. Xanthopoulos,PhD
  • Lead Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data